Genetic Gallstones: ABCB4, ABCG8, and Hereditary Risk

Are gallstones hereditary? Heritability estimates

Gallstones result from a complex interplay of genetic and environmental factors. Twin studies show a heritability of 25‑30% for cholesterol gallstones, meaning about one‑quarter of the risk is genetically determined. Family aggregation is well‑established: first‑degree relatives of gallstone patients have a 2‑4 fold increased risk compared to the general population.

However, most genetic variants are common, low‑penetrance polymorphisms rather than rare, high‑penetrance mutations. The latter occur in specific syndromes (e.g., LPAC, sitosterolemia, hereditary spherocytosis).

ABCB4 (MDR3) – low phospholipid‑associated cholelithiasis (LPAC)

The ABCB4 gene (ATP‑binding cassette subfamily B member 4, also called MDR3) encodes a phospholipid flippase that translocates phosphatidylcholine into bile. Heterozygous mutations cause Low Phospholipid‑Associated Cholelithiasis (LPAC) syndrome.

Clinical features of LPAC:

• Early‑onset gallstones (<40 years, often <30).
• Recurrent gallstones after cholecystectomy (stones form in the bile ducts).
• Intrahepatic sludge or microlithiasis.
• Poor response to UDCA monotherapy (requires higher doses).
• Increased risk of biliary complications (pancreatitis, cholangitis).

Diagnosis: Genetic testing (sequencing of ABCB4). Biliary lipid analysis shows very low phospholipid content (<10% of total lipids).

Treatment: High‑dose UDCA (15‑20 mg/kg/day) can prevent recurrence and dissolve existing stones in the ducts. Cholecystectomy alone is insufficient because stones recur in the bile ducts. Liver transplantation may be needed in severe cases with progressive cholestasis.

ABCG5/ABCG8 – sterolin and sitosterolemia

The ABCG5 and ABCG8 genes form a heterodimer (sterolin) that pumps plant sterols and cholesterol from enterocytes and hepatocytes into the intestinal lumen and bile. Mutations cause sitosterolemia (plant sterol accumulation) and increase cholesterol gallstone risk.

Key points:

• Common variants (e.g., ABCG8 p.D19H, p.T400K) are among the strongest genetic risk factors for cholesterol gallstones in the general population (odds ratio ~1.5‑2.0).
• Homozygous mutations cause sitosterolemia: xanthomas, premature atherosclerosis, macrothrombocytopenia, and gallstones.
• Treatment of sitosterolemia: ezetimibe, plant sterol‑restricted diet, and sometimes UDCA.

For typical gallstone patients, testing ABCG8 variants is not clinically indicated, but research continues to explore pharmacogenomics (e.g., response to ezetimibe or statins).

UGT1A1 – Gilbert’s syndrome and pigment stones

UGT1A1 encodes UDP‑glucuronosyltransferase 1A1, which conjugates bilirubin. Gilbert’s syndrome (homozygous for the (TA)7 promoter variant) reduces enzyme activity to ~30%, causing mild unconjugated hyperbilirubinemia.

• Unconjugated bilirubin is poorly soluble and can precipitate as calcium bilirubinate stones (pigment stones).
• Gilbert’s syndrome is a risk factor for black pigment stones, especially in patients with hemolysis (e.g., hereditary spherocytosis, sickle cell disease).
• In the absence of hemolysis, the gallstone risk increase is modest (odds ratio ~1.2‑1.5).

Testing UGT1A1 is not routine but may be considered in patients with recurrent pigment stones without obvious hemolysis.

Other genes: CYP7A1, HNF1A, APOB, LRP2

Several other genes have been implicated:

• CYP7A1: Rate‑limiting enzyme in bile acid synthesis (cholesterol 7α‑hydroxylase). Rare mutations cause severe cholestasis and gallstones (CTX-like phenotype). Common variants modestly affect risk.
• HNF1A (MODY3): Maturity‑onset diabetes of the young. Gallstone risk is increased (possibly due to altered cholesterol metabolism).
• APOB, APOE, LRP2: Lipid metabolism genes – some variants associated with gallstone risk in GWAS.
• TMEM147, SULT2A1, NR1H4 (FXR): Emerging candidates from recent studies.

Most of these are not currently used in clinical practice; they remain research targets.

When to suspect a genetic cause – clinical red flags

Genetic testing for gallstones is not routine. Consider in the following scenarios:

• Very early onset – gallstones diagnosed before age 30 (especially <20).
• Recurrent stones after cholecystectomy – stones in the common bile duct or intrahepatic ducts.
• Strong family history – multiple first‑degree relatives affected, especially across generations.
• Poor response to UDCA – despite appropriate selection for cholesterol stones.
• Associated features – hemolytic anemia (pigment stones), xanthomas (sitosterolemia), chronic cholestasis (LPAC).

If suspected, refer to a hepatologist or geneticist. Testing typically includes targeted sequencing of ABCB4, ABCG5/ABCG8, UGT1A1, and sometimes CYP7A1.

Clinical implications: testing, family screening, treatment

Identifying a genetic mutation can change management:

• LPAC (ABCB4): High‑dose UDCA (15‑20 mg/kg/day) lifelong; cholecystectomy alone insufficient; screen siblings for early detection.
• Sitosterolemia (ABCG5/ABCG8): Ezetimibe, dietary plant sterol restriction, monitor for atherosclerosis.
• Gilbert’s (UGT1A1) with pigment stones: Exclude hemolysis; no specific therapy except standard stone management; avoid UDCA (ineffective for pigment stones).
• Family screening: First‑degree relatives of LPAC patients should have abdominal ultrasound and possibly genetic testing if symptomatic.

For most gallstone patients, however, genetics does not alter the standard algorithm (observation, UDCA, or cholecystectomy). Lifestyle factors (diet, weight) remain dominant modifiable risks.

Interactive FAQ – Genetic gallstones

Disclaimer: This information is for educational purposes. Genetic testing for gallstones is not routine and should be guided by a specialist. For clinical management, consult a hepatologist or gastroenterologist at Vivekananda Hospital.